KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitis.

Jonathan I Silverberg, Andreas Wollenberg, Linda Stein Gold, Gil Yosipovitch, Peter Lio, Christian Vestergaard, Sonja Ständer, Jose Manuel Carrascosa, Gaia Gallo, Marta Casillas, Yuxin Ding, Fan Emily Yang, Evangeline Pierce, Helena Agell, James Del Rosso

Clin Exp Dermatol 51(6) 1012-1019

PMID41206702
PMCID-
DOI10.1093/ced/llaf490
发表日期2025-11-09
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: Lebrikizumab, a novel monoclonal antibody targeting interleukin-13, demonstrated a durable and deep response on skin and itch in patients treated for 104 weeks in recent phase III trials (ADvocate1, NCT04146363; ADvocate2, NCT04178967; ADjoin, NCT04392154). OBJECTIVES: To assess stability of response through 2 years of continuous lebrikizumab treatment in week 16 responders from ADvocate1 and ADvocate2 who continued the same treatment [lebrikizumab every 4 weeks (q4w), n = 99; lebrikizumab every 2 weeks (q2w), n = 82] in the long-term extension study ADjoin. METHODS: Week 16 response was defined as the Investigator's Global Assessment score of 0 or 1 with ≥ 2-point improvement from baseline, or ≥ 75% reduction in Eczema Area and Severity Index (EASI 75) without rescue medication. Stability was measured for EASI 75, EASI 90 and Pruritus Numeric Rating Scale (NRS) ≥ 3-point and ≥ 4-point improvement from baseline among week 16 responders who had achieved the specified endpoint at week 16. Stability was defined as maintenance of response for ≥ 80% of attended study visits from weeks 16 through 104 (ADjoin week 52). Observed data were analysed regardless of rescue medication or discontinuation from treatment. RESULTS: With 104 weeks of continuous lebrikizumab treatment, 96% and 81% of week 16 responders receiving lebrikizumab q4w (91% and 79% for q2w) showed stable EASI 75 and EASI 90 responses, respectively. Similarly, 94% and 88% of responders receiving lebrikizumab q4w (89% and 87% for q2w) showed stable responses for Pruritus NRS ≥ 3-point and ≥ 4-point improvement, respectively. CONCLUSIONS: The majority of lebrikizumab week 16 responders maintained stable efficacy in measures of skin and itch during 2 years of -treatment.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。